Psychotropic Drug Use in Intellectually Disabled Group-Home Residents with Behavioural Problems

Little is known about psychiatric and behavioural factors associated with psychotropic drug use and how appropriately these drugs are prescribed in settings for people with intellectual disabilities. The aim of this study was to measure the point prevalence of psychotropic drug use in a problem-behaviour group (PBG) consisting of intellectually disabled residents of group homes compared to a random group (RG), and to gain insight in possible factors that are associated with group membership. From all group homes in the Netherlands, 573 problematic residents were selected by the staff (one resident from each home) and 1479 residents were randomly sampled from all of the homes. Mental health problems were measured using the Reiss Screen for Maladaptive Behaviour and the Psychopathology Instrument for Mentally Retarded Adults. The response rate in the PBG was 68.9 % and in the RG 71.7 %. Psychotropics (excluding anticonvulsants) were used by 52.6 % of the PBG and by 22.8 % of the RG. Young age, psychotic, anxiety, and aggression symptoms were significantly associated with the PBG, as was the use of antipsychotics and antidepressants. The PBG more often used multiple (three or more) drugs (17.3 %) than the RG (7.3 %). A low prevalence of antidepressants or mood stabilisers, antipsychotics, and anxiolytics was found in residents with affective, psychotic, or anxiety symptoms. We conclude that psychotropic drug use in the PBG compared to the RG was high. It is likely that the group-home staff finds it difficult to deal with young people with socially disruptive behaviour, which is underlined by our finding of high prevalence of antipsychotics and multiple-drug therapy in the PBG. Finally, our findings suggest that a considerable number of residents with psychiatric or behavioural symptoms are undertreated.

References

• 1 Aman M G, Sarphare G, Burrow W H. Psychotropic drugs in group homes: Prevalence and relation to demographic/psychiatric variables.  Am J Ment Retard. 1995;  99 500-509
• 2 Bates W J, Smeltzer D J, Arnoczky S. Appropriate and inappropriate use of psychotherapeutic medications for institutionalized mentally retarded persons.  Am J Ment Defic. 1986;  90 363-370
• 3 Baumeister A A, Sevin J A, King B H. Neuroleptic medications. In Aman MG, Reiss S, editors Psychotropic Medications and Developmental Disabilities. The International Consensus Handbook. Columbus, OH: Ohio State University 1998: 133-150
• 4 Borthwick-Duffy S A. Epidemiology and prevalence of psychopathology in people with mental retardation.  J Consult Clin Psychol. 1994;  62 17-27
• 5 Campbell M, Malone P. Mental retardation and psychiatric disorders.  Hosp Community Psychiatry. 1991;  42 374-379
• 6 Clarke D. Physical treatments. In Read SG, editor Psychiatry in learning disability. London: W.B. Saunders Company Ltd 1997: 350-379
• 7 Jacobson J W. Problem behavior and psychiatric impairment within a developmentally disabled population III: Psychotropic medication.  Res Dev Disabil. 1988;  9 23-38
• 8 Kiernan C, Reeves D, Alborz A. The use of antipsychotic drugs with adults with learning disabilities and challenging behaviour.  J Intellect Disabil Res. 1995;  39 263-274
• 9 Koedoot P, Kok I. Gedragsproblematiek in GVT's: De omvang en aanpak van gedragsproblemen in semi-murale woonvoorzieningen voor verstandelijk gehandicapten. Utrecht: Nederlands Centrum Geestelijke Volksgezondheid 1996
• 10 Malt U F, Nystad R, Bache T, Noren O, Sjaastad M, Solberg K O. et al . Effectiveness of zuclopentixol compared with haloperidol in the treatment of behavioral disturbances in learning disabled patients.  Br J Psychiatry. 1995;  166 374-377
• 11 Matson J L, Minnen A v an, Hoogduin K. Handleiding: De Nederlandse versie van de Psychopathology Inventory for Mentally Retarded Adults. [Handbook: The Dutch version of the Psychopathology Instrument for Mentally Retarded Adults], Worthington (Ohio): IDS Inc 1994
• 12 Minnen A v an, Savelsberg P M, Hoogduin K AL. A Dutch version of the Psychopathology Inventory for Mentally Retarded Adults (PIMRA).  Res Dev Disabil. 1994;  15 269-278
• 13 Minnen A v an, Savelsberg P M, Hoogduin K AL. A Dutch version of the Reiss Screen of Maladaptive Behavior.  Res Dev Disabil. 1995;  16 43-49
• 14 Nordic Council on M edicines. Guidelines for DDD. Oslo: WHO collaborating Centre for Drug Statistics and Methodology 1995
• 15 Reiss S. The Reiss Screen for Maladaptive Behavior test manual. Worthington (Ohio): IDS Publishing 1988
• 16 Reiss S. Introduction. Handbook of Challenging Behavior: Mental Health Aspects of Mental Retardation. Worthington (Ohio): IDS Publishing Corporation 1994
• 17 Reiss S, Minnen A v an, Hoogduin K. Handleiding: De Nederlandse versie van de Reiss Screen for Maladaptive Behavior. (Handbook: The Dutch version of the Reiss Screen for Maladaptive Behavior). Worthington (Ohio): IDS Inc 1994
• 18 Rinck C. Epidemiology and psychoactive medication. In Aman MG, Reiss S, editors Psychotropic Medications and Developmental Disabilities. The International Consensus Handbook. Columbus, OH: Ohio State University 1998: 31-44
• 19 Rojahn J, Tasse M J. Psychopathology in mental retardation. In Jacobson JW, Mulick JA, editors Manual of diagnosis and professional practice in mental retardation. Washington DC, American Psychological Association 1996: 147-156
• 20 Schroijenstein Lantman-De Valk HMJ v an, Kessels A GH, Haveman M J, Maaskant M A, Urlings H FJ, Akker M  van den. Medicijngebruik door verstandelijk gehandicapten in instituten en gezinsvervangende tehuizen [Use of medication by mentally handicapped in institutions and group homes].  Ned Tijdschr Geneesk. 1995;  139 1083-1088
• 21 Senatore V, Matson J L, Kazdin A E. An inventory to assess psychopathology of mentally retarded adults.  Am J Ment Defic. 1985;  89 459-466
• 22 Singh N N, Ellis C R, Wechsler H. Psychopharmacoepidemiology of mental retardation: 1966 to 1995.  J Child Adolesc Psychopharmacol. 1997;  7 255-267
• 23 Sovner R, Pary R J, Dosen A, Geyde A, Barrera F J, Cantwell D P. et al .Antidepressants. In Aman MG, Reiss S, editors Psychotropic Medications and Developmental Disabilities. The International Consensus Handbook. Columbus, OH: Ohio State University 1998: 179-200
• 24 Spreat S, Conroy J W, Jones J C. Use of psychotropic drug medication in Oklahoma: A statewide survey.  Am J Ment Retard. 1997;  102 80-85
• 25 SPSS 6.0 Chicago: SPSS Inc .1996
• 26 Stone R K, Alvarez  W F, Ellman G, Hom A C, White J F. Prevalence and prediction of psychotropic drug use in California developmental centers.  Am J Ment Retard. 1989;  93 627-632
• 27 Szymanski L S. Mental retardation and mental health: Concepts, aetiology and incidence. In Bouras N, editor Mental health in mental retardation: Recent advances and practices. Cambridge, England: Cambridge University Press 1994: 19-33
• 28 Tuinier S, Verhoeven W MA. Pharmacological advances in mental retardation: A need for reconceptualization.  Curr Opin Psychiatry. 1994;  7 380-386
• 29 Waarde J v an, Stolker J J, Van R. Gedragsveranderingen bij mensen met een verstandelijke handicap begrepen en behandeld door consultatieve psychiatrie [Consultative psychiatry in services for people with intellectual disabilities].  Ned Tijdschr Geneesk. 1999;  143 1801-1804
• 30 Werry J S. Anxiolytics and sedatives. In Aman MG, Reiss S, editors Psychotropic Medications and Developmental Disabilities. The International Consensus Handbook. Columbus, OH: Ohio State University 1998: 201-214